It is made available under a CC-BY-NC-ND 4.0 International license .

# Mild and moderate COVID-19 during Alpha, Delta and Omikron pandemic waves in urban Maputo, Mozambique, December 2020-March 2022: a population-based surveillance study

- 3 Brecht Ingelbeen<sup>1,2#</sup>, Victória Cumbane<sup>3#</sup>, Ferão Mandlate<sup>3</sup>, Barbara Barbé<sup>1</sup>, Sheila Mercedes
- 4 Nhachungue<sup>3</sup>, Nilzio Cavele<sup>3</sup>, Cremildo Manhica<sup>3</sup>, Catildo Cubai<sup>3</sup>, Neusa Maimuna Carlos Nguenha<sup>3</sup>,
- 5 Audrey Lacroix<sup>4</sup>, Joachim Mariën<sup>1</sup>, Anja de Weggheleire<sup>5</sup>, Esther van Kleef<sup>1,2</sup>, Philippe Selhorst<sup>1</sup>,
- 6 Marianne AB van der Sande<sup>1,2</sup>, Martine Peeters<sup>4</sup>, Marc-Alain Widdowson<sup>1</sup>, Nalia Ismael<sup>3\*</sup>, Ivalda
- 7 Macicame<sup>3\*</sup>
- 8 <sup>1</sup> Instituut voor Tropische Geneeskunde, Antwerp, Belgium
- 9 <sup>2</sup> Julius Center for Health Sciences and Primary Care, Utrecht University, Utrecht, the Netherlands
- <sup>3</sup> Instituto Nacional de Saúde, Ministry of Health (MISAU), Marracuene, Mozambique
- <sup>4</sup> TransVIHMI (Recherches Translationnelles sur VIH et Maladies Infectieuses), Université de
- 12 Montpellier, Institut de Recherche pour le Développement, INSERM, Montpellier, France
- <sup>5</sup> Médecins sans Frontières, Brussels, Belgium
- 14 Correspondence: <u>bingelbeen@itg.be</u>
- 15 <sup>#</sup> and <sup>\*</sup>: Authors contributed equally

# 16 Abstract

- 17 In sub-Saharan Africa, reported COVID-19 numbers have been lower than anticipated, even when
- 18 considering populations' younger age. The extent to which risk factors, established in industrialised
- 19 countries, impact the risk of infection and of disease in populations in sub-Saharan Africa, remains
- 20 unclear. We estimated the incidence of mild and moderate COVID-19 in urban Mozambique and analysed
- 21 factors associated with infection and disease in a population-based surveillance study.
- 22 During December 2020-March 2022, households of a population cohort in Polana Caniço, Maputo,
- 23 Mozambique, were contacted biweekly. Residents reporting any respiratory sign, anosmia, or ageusia,
- 24 were asked to self-administer a nasal swab, for SARS-CoV-2 PCR testing. Of a subset of 1400
- 25 participants, dried blood spots were repeatedly collected three-monthly from finger pricks at home.
- 26 Antibodies against SARS-CoV-2 spike glycoprotein and nucleocapsid protein were detected using an in-
- 27 house developed multiplex antibody assay. We estimated the incidence of respiratory illness and COVID-
- 28 19, and SARS-CoV-2 seroprevalence. We used Cox regression models, adjusting for age and sex, to
- 29 identify factors associated with first symptomatic COVID-19 and with SARS-CoV-2 sero-conversion in
- 30 the first six months.
- 31 During 11925 household visits in 1561 households, covering 6049 participants (median 21 years, 54.8%
- 32 female, 7.3% disclosed HIV positive), 1895.9 person-years were followed up. Per 1000 person-years,
- 33 364.5 (95% CI 352.8-376.1) respiratory illness episodes of which 72.2 (95% CI 60.6-83.9) COVID-19
- 34 confirmed, were reported. Of 1412 participants, 2185 blood samples were tested (median 30.6 years,
- 35 55.2% female). Sero-prevalence rose from 4.8% (95%CI 1.1-8.6%) in December 2020 to 34.7% (95%CI
- 36 20.2-49.3%) in June 2021, when 3.0% were vaccinated. Increasing age (strong gradient in hazard ratio,
- HR, up to 15.70 in ≥70 year olds, 95% CI 3.74-65.97), leukaemia, chronic lung disease, hypertension, and
- 38 overweight increased risk of COVID-19. We found no increased risk of COVID-19 in people with HIV or
- 39 tuberculosis. Risk of COVID-19 was lower among residents in the lowest socio-economic quintile (HR
- 40 0.16, 95% CI 0.04-0.64), with no or limited handwashing facilities, and who shared bedrooms (HR 0.42,
- 41 95% CI 0.25-0.72). Older age also increased the risk of SARS-CoV-2 seroconversion (HR 1.57 in 60-69
- 42 year olds, 95%CI 1.03-2.39). We found no associations between SARS-CoV-2 infection risk and socio-
- 43 economic, behavioural factors and comorbidities.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 44 Active surveillance in an urban population cohort confirmed frequent COVID-19 underreporting, yet
- 45 indicated that the large majority of cases were mild and non-febrile. In contrast to industrialised countries,
- 46 deprivation did not increase the risk of infection nor disease.
- 47 Keywords: Population-based surveillance; COVID-19; SARS-CoV-2; Mozambique; Seroepidemiologic
- 48 studies; Pandemics

It is made available under a CC-BY-NC-ND 4.0 International license .

## 49 Introduction

- 50 Older age, deprivation, black ethnicity (compared to white) increased the risk of COVID-19 disease or
- 51 death in different contexts (1–3). Younger age groups less frequently manifested symptoms or were
- 52 hospitalised when infected, but also had lower infection rates (4,5). In sub-Saharan African countries,
- 53 reported COVID-19 cases and deaths were lower than expected from the infection prevalence measured in
- 54 sero-surveys and age-specific infection fatality (6.7). HIV increased the risk of COVID-19-related death
- 55 (8), as did widely established risk factors as hypertension, diabetes, or chronic kidney of pulmonary
- 56 disease (1). Higher COVID-19 incidence among deprived has been explained by inequalities in the ability
- 57 to work remotely, and by higher secondary infection rates within (more crowded) households (9).
- 58 The extent to which non-pharmaceutical interventions had an impact on COVID-19 incidence in sub-
- 59 Saharan African settings is still poorly understood. Other studies in Eastern Africa have shown a reduction
- 60 in deaths from acute respiratory infections (10).
- 61 In Mozambique, 184219 COVID-19 cases and 2010 deaths were reported during 2020-21, yet excess
- 62 deaths due to the pandemic have been estimated at 78100 (95% CI 54100-109000) (11). The excess
- 63 mortality rate (139 per 100000, 95% CI 96-194) was comparable to the global all-age estimate (120 per
- 64 100000, 95% CI 113–129). COVID-19 vaccination started on 7 March 2021. By 8 September 2021, 5.0%
- of the Mozambican population received at least one dose of vaccine. By 8 March 2022, 40.2% did.
- In Maputo City, the capital of Mozambique, in 2020-21, COVID-19 testing was centralised in two
- 67 COVID-19 management facilities, where mild/moderate cases were unlikely to go. We provide a
- 68 comprehensive description of the clinical range of mild and moderate COVID-19 in urban Maputo. We
- 69 then estimate SARS-CoV-2 (infection) sero-prevalence, COVID-19 (disease) incidence rates, and analyse
- 70 demographics, comorbidities, and exposures increasing the risk of infection and of disease.

# 71 Methods

- 72 Study design and population
- 73 Between December 2020 and March 2022, population based surveillance in urban Maputo consisted of
- two components: biweekly follow-up of households to record possible COVID-19 cases (acute respiratory
- 75 symptom, fever, anosmia, or ageusia) and three-monthly sero-surveys to track SARS-CoV-2 antibodies in
- 76 a subset of participants. Recruited households were embedded in the Health and Demographic
- 577 Surveillance System of Polana Caniço, covering 15,393 residents. Participants had to be residents since  $\geq 3$
- 78 months, and included all ages.
- 79 At baseline, household-level demographics, socio-economic, water- and sanitation conditions, individual
- 80 comorbidities, and behaviour potentially determining exposure were recorded in electronic questionnaires.
- 81 Subsequently, households were visited or phoned every two weeks during one year to detect possible
- 82 COVID-19 cases at the time of the visit or with symptom onset in the two weeks prior to the visit.
- 83 Possible cases were asked to self-administer a nasal swab for SARS-CoV-2 PCR testing. Symptoms
- 84 during the previous two weeks were recorded. If COVID-19 was confirmed, the case was followed up
- after 28 and 56 days to record clinical outcome.
- 86 For the repeated sero-survey, randomly selected participating household members from three age strata (0-
- $17, 18-49, and \ge 50$  years) were visited every three months during one year to collect dried blood spots
- from a fingerprick and (from 31 March 2021 onwards) record prior COVID-19 vaccination.
- 89 Laboratory procedures

It is made available under a CC-BY-NC-ND 4.0 International license .

90 Nasal swabs were self-administered at participants' homes or assisted by interviewers in participants


- 91 under 5 years of age, then transported in RNA Shield<sup>TM</sup> reagent. Real-time reverse-transcription PCR was
- 92 performed within the same day at Instituto Nacional de Saúde, Marracuene, Mozambique.
- 93 Dried blood spots, containing 450µl of blood sampled from a fingerprick in six circles (each
- <sup>94</sup> approximately 75ul) on dried blood spot filter paper (Whatman 903<sup>TM</sup> Protein Saver Card), were prepared
- 95 for testing by punching two discs of 4mm diameter (corresponding to 40 μl of blood), and eluted
- 96 overnight in 160 µL of hypertonic phosphate buffered saline-BSA (dilution 1:40, phosphate buffered
- saline-1 % BSA-0.15 % Tween, pH 7.4, Sigma-Aldrich). Before use in the immunoassay, eluted samples
  have been further diluted to 1:200 in hypertonic phosphate buffered saline-BSA, according to Mariën *et al*
- have been further diluted to 1:200 in hypertonic phosphate buffered saline-BSA, according to Mariën *et al* (12). We then used an in-house developed multiplex antibody assay for the detection of anti-SARS-CoV-2
- (12). We then used an in-house developed multiplex antibody assay for the detection of anti-SARS-CoV-2
   IgG: we coupled recombinant large spike glycoprotein S1 and S2 subunit, receptor-binding domain
- IgG: we coupled recombinant large spike glycoprotein S1 and S2 subunit, receptor-binding domain
   (RBD), and nucleocapsid-protein (NP) antigens derived from SARS-CoV-2 at Sino Biological to
- maximum of  $1.25 \square \times \square 10^{\circ}6$  paramagnetic MAGPLEX COOH-microsphere beads from Luminex
- 103 Corporation as antibody targets.  $150 \square \mu l$  of beads and diluted sera were added to each well, incubated at
- 104 room temperature, then washed with 200 ul/well of hypertonic phosphate buffered saline-BSA. Adding
- 105 biotin-labelled anti-human secondary IgG and streptavidin-R-phycoerythrin conjugate, another 30 min
- 106 incubation, samples were read on Luminex MagPix<sup>TM</sup> at Instituto Nacional de Saúde, Marracuene,
- 107 Mozambique. For each antigen target, a cut-off value of antibody detection was estimated by adding 2.5
- 108 standard deviations to the average value of 42 negative control samples from residents of Maputo,
- 109 collected prior to the pandemic and also spotted on filter paper. We used two citeria to determine
- seropositivity: (i) both RBD and NP above the cut-off, ensuring excellent specificity as demonstrated in
- 111 (12), and (ii) RBD above the cut-off, similar to assays used in most other SARS-CoV-2 sero-surveys (5).
- 112 After breakdown of the MagPix<sup>TM</sup> platform, serological testing for samples collected after August 2021
- 113 became unavailable.
- 114 Data analysis
- 115 We estimated incidence rates of acute respiratory illness and of COVID-19 from respectively the number
- 116 of possible cases and of confirmed COVID-19 cases, divided by the observation time. Because every
- 117 household visit recorded possible cases with onset during two weeks before the visit, observation time
- 118 consisted of the two weeks prior to each visit, or the time between visits if less than two weeks spanned
- 119 between consecutive visits. We analysed clinical signs and symptoms associated to COVID-19,
- comparing confirmed cases to SARS-CoV-2 negative cases, adjusting for age using unconditional logistic
   regression.
- 122 To identify participant demographic, health, socio-economic and behavioural characteristics associated
- 123 with COVID-19, we did a survival analysis fitting a Cox proportional hazards model with self-reported
- first confirmed COVID-19 as event variable, and observation time, censored after a first confirmed
- 124 Inst commed COVID-19 as event variable, and observation time, censored after a 1
- 125 COVID-19 episode, as time variable, adjusting for age and sex.
- 126 We estimated infection- and vaccination-induced SARS-CoV-2 sero-prevalence, by age group, based on
- 127 sero-survey samples collected up to 31 July 2021. Samples were SARS-CoV-2 sero-positive when
- 128 antibodies against RBD and NP were detected, as proposed by a validation study of the assay (12). To
- 129 ensure comparability to results with other sero-surveys, we analysed sero-prevalence based on antibodies
- 130 against RBD only.
- 131 To identify participant characteristics associated with SARS-CoV-2 infection (including asymptomatic),
- similar to the above survival analysis of first symptomatic COVID-19, we fitted a Cox proportional
- hazards model to sero-survey participants with  $\geq 2$  samples collected up to 31 July 2021. Events were
- 134 either a SARS-CoV-2 positive result following a negative result (sero-conversion) or an initial SARS-

It is made available under a CC-BY-NC-ND 4.0 International license .


- 135 CoV-2 positive result. Time consisted of three months prior to each sero-survey, or the time between
- 136 consecutive sero-surveys if less than three months spanned in-between, and was in case of sero-
- 137 conversion censored at the midpoint between the last negative test and the subsequent positive test.
- 138 Ethical considerations
- 139 The study protocol was approved by the Mozambican national health bio-ethics committee
- 140 (517/CNBS/2020) and the Antwerp University Hospital ethics committee (B3002020000123). Study
- 141 participants provided written informed consent at baseline for study participation, and again at the time of
- 142 collecting a nasal swab or at the first sero-survey visit.


#### 143 **Results**

- 144 Household surveillance of acute respiratory illness
- 145 Between 15 December 2020 and 31 March 2021, we conducted 11925 household visits in 1561
- 146 households, covering 6049 participants (Figure 1). Participants were median 21 years old (interquartile
- 147 range, IQR, 11-38 years), 3315 (54.8%) were female, and 435 (7.3%) disclosed to be HIV positive. 2694
- 148 (55.6% of 4841 with recorded socio-economic status) did not complete primary education and 93 (1.9%)
- 149 had higher education.



At least one household member with respiratory symptoms no









152 stacked by SARS-CoV-2 PCR test result, D. Geographical distribution of possible COVID-19 cases by result.

153

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 154 *Respiratory illness and COVID-19 incidence rate*

- 155 In the two weeks prior to the visits, 482 households reported at least one possible case in the household.
- 156 The incidence rate of respiratory illness was 364.5 (95% CI 352.8-376.1) per 1000 person-years (py, 691
- 157 possible cases in 611 participants; 1895.9 py followed up). Of 579 possible cases, a nasal swab was
- 158 collected and tested, median 5 days (IQR, 3-8 days) after symptom onset. SARS-CoV-2 was confirmed in
- 159 144 (24.9%) cases. The incidence rate of confirmed COVID-19 was 72.2 (95% CI 60.6 83.9) per 1000 py.
- 160 Among participants under 18 years old, this was 25.9 (95% CI 15.0-36.8) per 1000 py; in 18-49 year olds
- 161 it was 79.9 (95% CI 61.2-98.5) per 1000 py; in  $\geq$ 50 year olds, it was 188.3 (95% CI 141.8-234.9) per 1000
- 162 py. SARS-CoV-2 positivity of tested possible cases peaked at 39% in January 2021, at 39% in July 2021,
- 163 and at 55% in December 2021.

#### 164 Clinical signs and symptoms of mild and moderate COVID-19

- 165 Reported COVID-19 cases were median 36.4 years old (IQR 22.3-57.5 years) and 87 (60.4%) were female
- 166 (Table 1). Compared to SARS-CoV-2 negative cases (median age 26.0 years, IQR 10.8-49.3, 55.8%
- 167 female), COVID-19 cases had more frequently anosmia (age-adjusted odds ratio, aOR 2.36 95% CI 1.48-
- 168 3.58), ageusia (aOR, 2.29 95% CI 1.45-3.58), loss of appetite (aOR 2.21 95% CI 1.37-3.56), and chills
- 169 (aOR 1.78 95%CI 1.05-2.97). During the Omikron variant wave starting December 2021, the association
- 170 with each of these symptoms disappeared (anosmia aOR 1.1 95% CI 0.46-2.56, ageusia 0.70 95% CI 2.29-
- 171 1.62, loss of appetite 1.25 95% CI 0.52-2.96, chills 0.88 95% CI 0.28-2.49).
- 172 Table 1. Clinical signs and symptoms associated with SARS-CoV-2 confirmation among acute respiratory illness
- 173 (possible COVID-19 cases) reported during December 2020-March 2022.

Factors	Confirmed		Negative		Crude	odds ratio	Age-adjusted odds ratio		
	CoV-2 (N	(=148)	CoV-2 (N	(=435)					
	n	%	n	%	OR	95%CI	aOR	95% C	
Age*: 0-9 years	7	4.9	90	21.5	ref				
10-19 years	18	12.5	79	18.9	2.93	1.21-7.87			
20-29 years	34	23.6	62	14.8	7.05	3.10-18.3			
30-39 years	18	12.5	48	11.5	4.82	1.95-13.2			
40-49 years	14	9.7	37	8.8	4.86	1.87-13.8			
50-59 years	24	16.7	46	11.0	6.71	2.82-17.9			
60-69 years	22	15.3	40	9.5	7.07	2.92-19.1			
70+ years	7	4.9	17	4.1	5.29	1.62-17.4			
Sex*: Female	87	60.4	234	55.8	1.21	0.82-1.78	1.19	0.81-1.7	
Clinical signs/symptoms									
Cough	117	89.3	326	86.0	1.36	0.75-2.63	1.52	0.82-2.9	
Headache	81	61.8	217	57.3	1.21	0.81-1.82	1.14	0.75-1.7	
Rhinorrhoea	69	52.7	221	58.3	0.80	0.53-1.19	0.86	0.57-1.2	
Throat pain	54	41.2	131	34.6	1.33	0.88-1.99	1.22	0.80-1.8	
Ageusia	47	35.9	69	18.2	2.51	1.61-3.91	2.29	1.45-3.	
Oxygen saturation <95%	16/48	33.3	36/151	23.8	1.60	0.78-3.22	1.54	0.74-3.	
Anosmia	43	32.8	63	16.6	2.45	1.55-3.85	2.36	1.48-3.	
Fatigue	41	31.3	95	25.1	1.36	0.88-2.10	1.26	0.80-1.9	
Loss of appetite	39	29.8	62	16.4	2.19	1.37-3.48	2.21	1.37-3.5	
Fever	33	25.2	96	25.3	0.99	0.62-1.56	1.10	0.68-1.7	
Chills	29	22.1	50	13.2	1.87	1.12-3.10	1.78	1.05-2.9	
Joint pain	29	22.1	49	12.9	1.91	1.14-3.17	1.59	0.90-2.5	
Chest pain	25	19.1	60	15.8	1.25	0.74-2.08	1.10	0.64-1.8	
Myalgia	24	18.3	49	12.9	1.51	0.87-2.56	1.24	0.70-2.1	
Nausea	10	7.6	23	6.1	1.28	0.57-2.69	1.29	0.57-2.7	
Dyspnoe	9	6.9	36	9.5	0.70	0.31-1.44	0.62	0.27-1.3	
Diarrhoea	8	6.1	26	6.9	0.88	0.37-1.92	0.86	0.35-1.8	
Vomit	7	5.3	19	5.0	1.07	0.41-2.50	1.32	0.49-3.2	
Rash	3	2.3	3	0.8	2.94	0.54-16.0	2.98	0.54-16	
Nose bleeding	1	0.8	3	0.8	0.95	0.05-7.5	0.99	0.05-7.9	
Change of consciousness	0	0.0	3	0.8					

<sup>\*</sup> age and sex missing of 16 possible cases, clinical signs and symptoms missing of 69 possible cases.

It is made available under a CC-BY-NC-ND 4.0 International license .

175 Of 92 confirmed COVID-19 cases followed up after 28 days, of whom 54 again after 56 days, one (1.1%)

176 died.

177 Characteristics associated with (symptomatic) COVID-19

178 Increasing age (in  $\geq$ 70 year olds hazard ratio (HR) 15.70, 95% CI 3.74-65.97) and several reported

179 comorbidities increased the risk of symptomatic COVID-19: leukaemia, chronic lung disease, overweight,

180 underweight, diabetes, chronic heart disease, and hypertension (Table 2). We found no increased risk of

181 COVID-19 in people with HIV (HR 0.80, 95% CI 0.37-1.76) or with (a history of) tuberculosis (HR 0.93,

182 95% CI 0.33-2.58). The risk of COVID-19 was lower in people belonging to the lowest socio-economic

183 quintile (HR 0.16, 95% CI 0.04-0.64), in households with no or limited handwashing facilities, and in

households where bedrooms were shared with 3 or more household members (HR 0.42, 95% CI 0.25-

185 0.72).

186 *Table 2. Demographic, socio-economic and behavioural characteristics associated with first confirmed COVID-19* 

187 among among acute respiratory illness (possible COVID-19 cases) reported in population-based surveillance during

<sup>188</sup> December 2020-March 2022, using a Cox regression model adjusting for age and sex.

Characteristic			Cohort participants		rted )VID-		ge-/sex-adjusted rd ratio
		Ν	%	19 N	%	HR	95%CI
Age	0-9 years	1331	22.0	7	5.1	ref	<b>J</b> 570C1
8-	10-19	1570	26.0	18	13.1	2.63	0.72-9.56
	20-29	1128	18.6	30	21.9	9.00	2.72-29.84
	30-39	644	10.6	17	12.4	4.17	1.04-16.68
	40-49	519	8.6	14	10.2	6.42	1.70-24.2
	50-59	406	6.7	24	17.5	9.94	2.73-36.1
	60-69	318	5.3	20	14.6	14.33	4.04-50.8
	$\geq 70$	133	2.2	7	5.1	15.70	3.74-65.9
Sex	Male	2804	46.4	55	40.1	ref	
	Female	3245	53.6	82	59.9	1.10	0.70-1.72
Socio-economic	Lowest (compared to	836	16.3	6	4.9	0.16	0.04-0.6
quintile	other quintiles)						
	1. lowest	836	16.3	6	4.9	0.25	0.06-1.1
	2. low	1015	19.8	27	22.1	1.82	0.86-3.8
	3. med.	1063	20.7	15	12.3	ref	
	4. med./high	1078	21.0	31	25.4	1.71	0.81-3.6
	5. highest	1132	22.1	43	35.2	1.95	0.95-3.9
Education	None	88	1.9	3	2.4	0.50	0.30-0.8
	Primary	2646	55.8	59	46.8	ref	
	Secondary	1735	36.6	56	44.4	1.07	0.45-2.5
	Higher	277	5.8	8	6.3	0.95	0.23-3.9
Health worker		196	3.2	4	5.1	1.39	0.51-3.8
Reported comorbidities	HIV	434	7.3	7	8.9	0.79	0.36-1.74
	(history of) tuberculosis	178	3.0	4	5.1	0.99	0.36-2.74
	hypertension	575	9.6	22	27.8	1.86	1.02-3.3
	diabetes	68	1.1	3	3.8	2.14	0.66-6.9
	asthma	291	4.9	4	5.1	1.11	0.41-3.04
	chronic lung disease	37	0.6	4	5.1	9.69	3.51-26.7
	chronic heart disease	51	0.9	2	2.5	2.11	0.51-8.6
	leukaemia	51	0.9	2	2.5	28.53	3.92-207.6
BMI*	underweight	817	38.2	12	15.8	1.45	0.68-3.1
	normal	802	37.5	27	35.5	ref	
	overweight	281	13.1	19	25.0	1.87	1.02-3.4
	obesity	237	11.1	18	23.7	2.09	1.08-4.0
Smoking	non smoker	5738	95.8	74	93.7	ref	
	(ex-)smoker	251	4.2	5	6.3	1.09	0.42-2.78
Public transportation	none	3948	66.0	39	49.4	ref	
	bus/train	2013	33.7	40	50.6	1.50	0.95-2.3


It is made available under a CC-BY-NC-ND 4.0 International license .

	moto taxi/shared taxi	19	0.3	0	0.0		
Sharing bedroom	1-2 pers.	3311	55.6	61	77.2	ref	
-	3 or more pers.	2646	44.4	18	22.8	0.42	0.25-0.72
Sharing toilet with oth	her household	896	15.0	15	19.0	1.40	0.80-2.46
Handwash facility	sink/faucet	1748	29.3	35	44.3	ref	
-	bucket/jar/kettle	1204	20.2	9	11.4	0.38	0.18-0.79
	none	3005	50.4	35	44.3	0.54	0.34-0.87
Water available in	yes	2153	36.1	35	44.3	ref	
house	no	3804	63.9	44	55.7	0.74	0.48-1.16

189 \*in ≥16 year olds

190 Infection-induced SARS-CoV-2 sero-prevalence

- 191 2185 samples collected until 31 July 2021 of 1412 sero-survey participants (median age 30.6 years, IQR
- 192 13.7-57.6; 38.2% >50 years old; 55.2% female) were tested. 301 participants (21.3%) tested positive
- 193 (antibodies against RBD and NP) at least once. 34 (45.3%) out of 75 with a test subsequent to positive
- 194 test, seroreverted.
- 195 Crude sero-prevalence increased from 4.8% (95%CI 1.1-8.6) in December 2020 to 34.2% (95%CI 23.4-
- 45.1) in June 2021, when 2.7% of participants were vaccinated with at least one dose of vaccine (Figure 196
- 197 2). Sero-prevalence increased strongest in  $\geq$ 50 year olds, peaking at 51.6% (95%CI 34.0-69.2) in June
- 2021, when 3.2% was vaccinated, yet declined to 41.6% (95% CI 26.5-56.7) in July 2021 when 10.9% was 198
- 199 vaccinated.



 $\begin{array}{c} 200\\ 201 \end{array}$ 

Figure 2. Infection- and vaccine-induced SARS-CoV-2 sero-prevalence by age group, December 2020 - July 2021. 202  $N_{0-17 years} = 647, N_{18-49 years} = 612, N_{\geq 50 years} = 882.$ 

- 203 Crude sero-prevalence based on antibodies against RBD only was higher, rising from 10.5% (95% CI 5.1-
- 15.9%) in December 2020 to 46.5% (95% CI 36.7-56.3) in July 2021, without decrease in sero-prevalence 204 205 from June to July 2021 (Supplementary table in Appendix).
- 206 Characteristics associated with SARS-CoV-2 infection
- 207 Older age increased the risk of SARS-CoV-2 infection (HR 60-69 versus 0-9 years 1.57, 95% CI 1.03-
- 208 2.39, Table 3). We found no association between SARS-CoV-2 infection risk and socio-economic,
- 209 behavioural factors and comorbidities.
- 210

It is made available under a CC-BY-NC-ND 4.0 International license .

211 Table 3. Demographic, socio-economic and behavioural characteristics associated with SARS-CoV-2 infection

(including asymptomatic) among sero-survey participants with  $\geq 2$  samples tested during December 2020-July 2021,

213 *using a Cox regression model adjusting for age and sex.* 

Characteristic		Sero-survey		SARS-0		SARS-CoV-2 age-/sex-		
		partici		infec		adjusted	hazard ratio	
		Ν	%	Ν	%	HR	95%C	
Age	0-9 years	223	15.9	35	12.2	ref		
	10-19	305	21.7	58	20.2	1.11	0.73-1.69	
	20-29	161	11.5	28	9.8	0.93	0.56-1.53	
	30-39	114	8.1	14	4.9	0.82	0.44-1.5	
	40-49	68	4.8	15	5.2	1.11	0.61-2.04	
	50-59	240	17.1	54	18.8	1.32	0.86-2.0	
	60-69	202	14.4	57	19.9	1.57	1.03-2.3	
	≥70	93	6.6	26	9.1	1.20	0.72-2.0	
Sex	Male	630	44.8	128	44.6	ref		
	Female	776	55.2	159	55.4	0.94	0.74-1.13	
Socio-economic	Lowest (compared to	100	157	24	12.0	0.83	0.58-1.2	
quintile	other quintiles)	190	15.7	34	13.9			
•	1. lowest	190	15.7	34	13.9	0.71	0.46-1.0	
	2. low	210	17.4	44	18.0	1.00	0.67-1.4	
	3. med.	234	19.4	54	22.0	ref		
	4. med./high	259	21.4	46	18.8	0.69	0.46-1.0	
	5. highest	316	26.1	67	27.3	0.80	0.56-1.1	
Education	None	738	62.5	168	67.5	1.26	0.94-1.7	
Laurunon	Primary	356	30.2	62	24.9	ref	017 1 117	
	Secondary	63	5.3	14	5.6	1.25	0.70-2.2	
	Higher	23	1.9	5	2.0	1.29	0.52-3.2	
Health worker	Ingher	54	3.9	12	4.3	1.11	0.62-1.9	
Reported	HIV	118	12	20	10.9	0.82	0.51-1.3	
comorbidities	(history of) tuberculosis	47	4.8	20 7	3.8	0.87	0.40-1.8	
comoroidities	hypertension	209	21.2	, 49	26.8	0.91	0.61-1.3	
	diabetes	27	2.7	11	6	1.65	0.88-3.1	
	asthma	59	6.0	14	7.7	1.23	0.71-2.1	
	chronic lung disease	6	0.6	2	1.1	2.48	0.61-10.0	
	chronic heart disease	12	1.2	1	0.5	0.40	0.06-2.8	
	leukaemia	12	0.1	1	0.5	1.27	0.17-9.2	
BMI*	underweight	258	29.5	52	26.8	0.72	0.35-1.4	
DIVII	normal	352	40.3	52 69	20.8 35.6	ref	0.55-1.4	
	overweight	126	14.4	30	15.5	1.08	0.69-1.7	
	obesity	120	15.8	43	22.2	1.03	0.81-1.9	
Smoking	non smoker	927	15.8 94	172	22.2 94	ref	0.01-1.9	
SHIOKINg	(ex-)smoker	59	6	172	6	0.67	0.35-1.2	
Dublic transportation		59 587		109	59.9	ref	0.55-1.2	
Public transportation	none bus/train	395	59.6	71	39.9 39.0		0.62.1.1	
		393	40.1 0.3	2	39.0 1.1	0.85 1.95	0.63-1.1 0.47-8.0	
Chaning hadroom	moto taxi/shared taxi		0.3 58.7	178			0.47-8.0	
Sharing bedroom	1-2 pers.	805			63.6 26.4	ref	0 66 1 0	
Charing toilst with -4-	3 or more pers.	566	41.3	102	36.4	0.84	0.66-1.0	
Sharing toilet with othe		214	15.6	37	13.2	0.80	0.57-1.1	
Handwash facility	sink/faucet	511	37.3	110	39.3	ref	0.00.1.5	
	bucket/jar/kettle	267	19.5	51	18.2	1.11	0.80-1.5	
***	none	593	43.3	119	42.5	0.98	0.75-1.2	
Water available in	yes	581	42.4	118	42.1	ref	0.05.1.0	
house	no	790	57.6	162	57.9	1.08	0.85-1.3	

214 \*in  $\geq$ 16 year olds

## 215 **Discussion**

216 Population-based COVID-19 surveillance in an urban population cohort in Mozambique confirmed that

217 even during the acute phase of the pandemic the large majority of SARS-CoV-2 infections were

asymptomatic, (symptomatic) COVID-19 cases were mild, and three in four were non-febrile.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 219 Three COVID-19 peaks were distinct and died out after a few weeks, while other respiratory illness
- 220 (SARS-CoV-2 negative) continued to be reported throughout 2021. Sudden drops in COVID-19 incidence
- after peaks while respiratory pathogens other than SARS-CoV-2 continue to circulate, indicate that newly
- 222 introduced COVID-19 variants (Alpha, Delta, Omikron) could quickly spread despite non-pharmaceutical
- interventions. Nonetheless, transmission slowed when infection-induced seroprevalence (e.g., 11.2% in
- March 2021) was still lower than the herd immunity threshold anticipated from the Alpha variants'
- reported transmissibility (13).
- 226 Surveillance started in December 2020 when the Beta variant had spread for 3 months through
- 227 neighbouring South Africa, and two weeks before a surge in cases in Mozambique. Infection-induced
- seroprevalence of 4.8% in December 2020 was lower than the corrected pooled 16.2% reported in other
- African countries that month (5). Limited spread of wild type virus and the Beta variant during the first
- 230 year of the pandemic contrasting to neighbouring South Africa and Eswatini could result from limited
- seeding through imported cases, limited mobility within the city and country, and longer maintained nonpharmaceutical interventions compared to its neighbours (14). The eventual surge in cases in January 2021
- followed relaxed non-pharmaceutical interventions for the end-of-year holidays coinciding with the
- presumed introduction of the Alpha variant with increased transmissibility (13).
- 235 SARS-CoV-2 sero-prevalence rose to 34.7% in June 2021, still far below the pooled 76% infection-
- 236 induced seroprevalence reported in other African countries. Only a fraction of that difference in sero-
- 237 prevalence can be explained by serological test specificity. Our analysis of SARS-CoV-2 sero-positivity
- comparing several SARS-CoV-2 antigen targets demonstrated a difference of up to 12%, thus cannot
- explain the twice higher sero-prevalence in other sero-surveys in sub-Saharan Africa. A diagnostic
- 240 performance study of the serological immunofluorescence assay supported the use of RBD and NP for
- IgG detection (12). A study using the same assay however showed decreasing sero-prevalence as a result
- of waning NP-specific IgG after three months (15). This could explain the decreasing sero-prevalence
- observed in July 2021.
- 244 The observed effect of age, obesity, and chronic conditions on the risk of mild disease was similar to the
- 245 effect on risk of severe disease or death reported elsewhere (1,16). While HIV and (history of)
- tuberculosis have been associated with COVID-19-related death (8), we observed no increased risk of
- 247 infection nor of disease. Also, deprivation, increasing the risk of infection, disease and severity in several
- settings (1,2,17), did not affect the risk of SARS-CoV-2 infection in this population of Maputo city.
- 249 Several indicators of deprivation, such as belonging to the lowest wealth quintile, no education, absence of
- 250 handwash facilities, were even associated with a lower risk of COVID-19.
- 251 Among cases of respiratory illness, only anosmia, ageusia, loss of appetite and chills increased the
- 252 probability of COVID-19, yet none of those symptoms was reported by more than a third of cases and the
- association disappeared in cases from December 2021 onwards, presumably Omikron cases. Symptoms'
- 254 poor predictive value, in combination with continued reporting of other respiratory illness, hampers
- diagnosis of mild/moderate COVID-19 on clinical grounds alone (18).

## 256 Conclusion

- 257 Active surveillance in an urban population cohort confirmed frequent COVID-19 underreporting, yet
- 258 indicated that the large majority of cases were mild and non-febrile. In contrast to industrialised countries,
- 259 deprivation did not increase the risk of infection nor disease.
- 260

It is made available under a CC-BY-NC-ND 4.0 International license .

## 261 Transparency declaration

All authors declare no competing interests. The work was funded by a European & Developing Countries Clinical Trials Partnership (EDCTP) project (RIA2020EF-3031). The funders had no role in study design,

264 data collection and analysis, decision to publish, or preparation of the manuscript.

## 265 Data availability

266 Pseudonymized data supporting the findings of this study/publication are retained at the Institute of

- 267 Tropical Medicine, Antwerp and can be made available after approval of a motivated and written request
- 268 to ITMresearchdataaccess@itg.be. Study protocol, data dictionaries, scripts for conducting the analysis,
- and anonymized data, without geo-located or other data that could allow identification, are available on
- 270 <u>https://github.com/ingelbeen/africover-git</u>.

#### 271 Acknowledgements

- 272 We thank participants of the Polana Caniço Health and Demographic Surveillance System, interviewers,
- teams involved in laboratory testing of samples (Claudia Machume, Gercio Cuamba, Caro Van Geel), data
- 274 management (Alberto Machaze, Eben Matavele, Harry van Loen), and study monitors (Dimpall Asmucrai,
- 275 Carolien Hoof).

# 276 References

- Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated
   with COVID-19-related death using OpenSAFELY. Nature [Internet]. 2020 Aug 20 [cited 2020
   Aug 17];584(7821):430–6. Available from: https://www.nature.com/articles/s41586-020-2521-4
- Vandentorren S, Smaïli S, Chatignoux E, Maurel M, Alleaume C, Neufcourt L, et al. The effect of
   social deprivation on the dynamic of SARS-CoV-2 infection in France: a population-based
   analysis. Lancet Public Heal [Internet]. 2022 Feb [cited 2022 Feb 24];7(3):e240–9. Available from:
   http://www.thelancet.com/article/S246826672200007X/fulltext
- Mathur R, Rentsch CT, Morton CE, Hulme WJ, Schultze A, MacKenna B, et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. Lancet [Internet]. 2021 Apr 30 [cited 2021 May 10];397(10286):1711–24. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33939953
- 289 4. Davies NG, Klepac P, Liu Y, Prem K, Jit M, Eggo RM. Age-dependent effects in the transmission 290 and control of COVID-19 epidemics. Nat Med [Internet]. 2020 Jun 16 [cited 2020 Jun 291 17]:26:1205–11. Available from: http://www.nature.com/articles/s41591-020-0962-9
- Bergeri I, Whelan MG, Ware H, Subissi L, Nardone A, Lewis HC, et al. Global SARS-CoV-2
  seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of
  standardized population-based studies. PLoS Med [Internet]. 2022 Nov 1 [cited 2023 Dec
  12];19(11). Available from: https://pubmed.ncbi.nlm.nih.gov/36355774/
- Lewis HC, Ware H, Whelan M, Subissi L, Li Z, Ma X, et al. SARS-CoV-2 infection in Africa: A
  systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to
  December 2021. BMJ Glob Heal. 2022;7(8):1–15.
- 299 7. O'Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, et al. Age300 specific mortality and immunity patterns of SARS-CoV-2. Nature [Internet]. 2020 Nov 2 [cited
  301 2020 Nov 18]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/33137809
- Boulle A, Davies MA, Hussey H, Ismail M, Morden E, Vundle Z, et al. Risk Factors for
   Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western
   Cape Province, South Africa. Clin Infect Dis [Internet]. 2021 Aug 29 [cited 2020 Oct
   8];73(7):E2005–15. Available from: https://pubmed.ncbi.nlm.nih.gov/32860699/
- 306
   9. Laajaj R, Webb D, Aristizabal D, Behrentz E, Bernal R, Buitrago G, et al. Understanding how socioeconomic inequalities drive inequalities in COVID-19 infections. Sci Rep [Internet].
- 308 2022;12(1). Available from: https://doi.org/10.1038/s41598-022-11706-7

It is made available under a CC-BY-NC-ND 4.0 International license .

- 309 10. Otiende M, Nyaguara A, Bottomley C, Walumbe D, Mochamah G, Amadi D, et al. Impact of
  310 COVID-19 on mortality in coastal Kenya: a longitudinal open cohort study. Nat Commun 2023
  311 141 [Internet]. 2023 Oct 28 [cited 2023 Dec 13];14(1):1–9. Available from:
  312 https://www.nature.com/articles/s41467-023-42615-6
- Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al. Estimating excess
  mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality,
  2020–21. Lancet [Internet]. 2022 Apr 16 [cited 2023 Jun 22];399(10334):1513–36. Available
  from: https://linkinghub.elsevier.com/retrieve/pii/S0140673621027963
- Mariën J, Ceulemans A, Michiels J, Heyndrickx L, Kerkhof K, Foque N, et al. Evaluating SARSCoV-2 spike and nucleocapsid proteins as targets for antibody detection in severe and mild
  COVID-19 cases using a Luminex bead-based assay. J Virol Methods [Internet]. 2021 Feb 1 [cited
  2022 Jun 20]:288. Available from: https://pubmed.ncbi.nlm.nih.gov/33227340/
- 321 13. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. Estimated
  322 transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science (80-) [Internet].
  323 2021 Apr 9 [cited 2023 Dec 14];372(6538). Available from:
  324 http://www.asianaa.arg/dai/10.1126/asianaa.abg2055
- 324 https://www.science.org/doi/10.1126/science.abg3055
- Hale T, Angrist N, Goldszmidt R, Kira B, Petherick A, Phillips T, et al. A global panel database of
  pandemic policies (Oxford COVID-19 Government Response Tracker). Nat Hum Behav [Internet].
  2021;5(4):529–38. Available from: http://dx.doi.org/10.1038/s41562-021-01079-8
- Mariën J, Ceulemans A, Bakokimi D, Lammens C, Ieven M, Heytens S, et al. Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium. Fam Pract [Internet]. 2021 Aug 27 [cited 2021 Sep 1]; Available from: https://academic.oup.com/fampra/advance-article/doi/10.1093/fampra/cmab094/6358549
- Bocherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133
  UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. Br Med J [Internet]. 2020 [cited 2020 May 28];369:m1985.
  Available from: https://isaric4c.net
- Mena GE, Martinez PP, Mahmud AS, Marquet PA, Buckee CO, Santillana M. Socioeconomic
   status determines COVID-19 incidence and related mortality in Santiago, Chile. Science (80-).
   2021;372(6545).
- Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, et al. Prediction models for
  diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ [Internet]. 2020
  Apr 7 [cited 2022 Jun 17];369. Available from: /pmc/articles/PMC7222643/
- 342

It is made available under a CC-BY-NC-ND 4.0 International license .

#### 343 Appendix

Supplementary Table 1. Infection- and vaccine-induced SARS-CoV-2 seroprevalence based on detection
 of antibodies against different SARS-CoV-2 antigens

3													
month	antibody detection		<b>RBP</b> and <b>NP</b> positive			two out of RBD, NP and S1S2 positive				RBD positive (regardless of S1S2 and NP)			
		n	prop	95%CI		n	prop	95%CI		n	prop	prop 95%(	
2020-12	negative	118	0.952	0.914	0.989	112	0.903	0.851	0.955	111	0.895	0.841	0.949
2020-12	positive after infection	6	0.048	0.011	0.086	12	0.097	0.045	0.149	13	0.105	0.051	0.159
2021-01	negative	433	0.945	0.925	0.966	416	0.908	0.882	0.935	399	0.871	0.840	0.902
2021-01	positive after infection	25	0.055	0.034	0.075	42	0.092	0.065	0.118	59	0.129	0.098	0.160
2021-02	negative	205	0.911	0.874	0.948	195	0.867	0.822	0.911	192	0.853	0.807	0.900
2021-02	positive after infection	20	0.089	0.052	0.126	30	0.133	0.089	0.178	33	0.147	0.100	0.193
2021-03	negative	465	0.884	0.857	0.911	447	0.850	0.819	0.880	436	0.829	0.797	0.861
2021-03	positive after infection	59	0.112	0.085	0.139	77	0.146	0.116	0.177	88	0.167	0.135	0.199
2021-03	positive after vaccination	2	0.004	-0.001	0.009	2	0.004	-0.001	0.009	2	0.004	-0.001	0.009
2021-04	negative	244	0.758	0.711	0.805	238	0.739	0.691	0.787	212	0.658	0.607	0.710
2021-04	positive after infection	75	0.233	0.187	0.279	81	0.252	0.204	0.299	107	0.332	0.281	0.384
2021-04	positive after vaccination	3	0.009	-0.001	0.020	3	0.009	-0.001	0.020	3	0.009	-0.001	0.020
2021-05	negative	181	0.733	0.678	0.788	179	0.725	0.669	0.780	163	0.660	0.601	0.719
2021-05	positive after infection	62	0.251	0.197	0.305	64	0.259	0.204	0.314	79	0.320	0.262	0.378
2021-05	positive after vaccination	4	0.016	0.000	0.032	4	0.016	0.000	0.032	5	0.020	0.003	0.038
2021-06	negative	48	0.658	0.549	0.766	46	0.630	0.519	0.741	42	0.575	0.462	0.689
2021-06	positive after infection	23	0.315	0.209	0.422	25	0.342	0.234	0.451	29	0.397	0.285	0.510
2021-06	positive after vaccination	2	0.027	-0.010	0.065	2	0.027	-0.010	0.065	2	0.027	-0.010	0.065
2021-07	negative	143	0.665	0.602	0.728	143	0.665	0.602	0.728	115	0.535	0.468	0.602
2021-07	positive after infection	61	0.284	0.223	0.344	61	0.284	0.223	0.344	86	0.400	0.335	0.465
2021-07	positive after vaccination	11	0.051	0.022	0.081	11	0.051	0.022	0.081	14	0.065	0.032	0.098

346 RBD= receptor-binding domain (of the spike protein), NP=nucleocapsid protein, S1S2=spike glycoprotein S1 and S2 subunit